GSK deal revives Spero’s clinical plan for oral antibiotic

After a months-long search for a partner, Spero has reached a deal with GSK that will enable the biotech to conduct a second Phase III trial of its oral carbipenem antibiotic for complicated urinary tract infections (cUTIs).

The deal gives Spero Therapeutics Inc. (NASDAQ:SPRO) a lifeline during a difficult year in which it had suspended its commercial activities, its cash reserves had dwindled and its stock had dipped below $1 intermittently...